| Report ID | 282242 |
| Drug Identification Number | 02531372 |
| Brand name | JAMP DAPAGLIFLOZIN |
| Common or Proper name | Dapagliflozin |
| Company Name | JAMP PHARMA CORPORATION |
| Market Status | MARKETED |
| Active Ingredient(s) | DAPAGLIFLOZIN |
| Strength(s) | 10MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | Bottle of 30 tablets |
| ATC code | A10BK |
| ATC description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2026-04-06 |
| Estimated end date | 2026-09-30 |
| Actual end date | 2026-04-07 |
| Shortage status | Actual shortage |
| Updated date | 2026-04-07 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 1310 RUE NOBEL BOUCHERVILLE, QUEBEC CANADA J4B 5H3 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2026-04-07 | French | Compare |
| v3 | 2026-04-07 | English | Compare |
| v2 | 2026-04-06 | French | Compare |
| v1 | 2026-04-06 | English | Compare |
Showing 1 to 4 of 4